As for ovarian cancer, first proof-of-concept trials have shown a significant activity of PARP inhibitors in women with advanced breast cancer and BRCA1-2 mutations [43], reporting ORR to olaparib nearly to 40% and median PFS 5.7 months in the overall population and ORR of 54% in TNBC patients [59]. The gene discussed is BRCA1; the disease is breast carcinoma.